The adverse events presented below are listed in accordance with the damage to organs and organ systems and frequency of occurrence.
Frequency of occurrence is defined as follows: very often (> 1/10), often (> 1/100 and <1/10), infrequently (> 1/1 000 and <1/100). rarely (> 1/10 000 and <1/1 000), very rarely (<1/10 000. including individual cases). Frequency categories were formed on the basis of clinical studies of the drug.
Frequency of occurrence of undesirable phenomena
Disturbances from the nervous system
Often: headache.
Disturbances from the skin and subcutaneous tissues
Often: sweating.
Disturbances from the musculoskeletal system and connective tissue Often: myalgia, arthralgia.
General disorders and disorders at the site of administration
Often: fever, malaise, chills, weakness.
Redness, swelling in the area of injection, soreness, bruising, compaction at the injection site.
These phenomena usually pass independently after 1-2 days.
Adverse events observed during post-marketing surveillance
Disturbances from the hematopoietic and lymphatic system: thrombocytopenia, transitional lymphadenopathy.
Disturbances from the immune system: allergic reactions, in rare cases leading to the development of shock, angioedema.
Impaired nervous system: neuralgia, paresthesia (unusual sensations such as burning, numbness, etc.), febrile convulsions, neurological disorders such as encephalomyelitis, neuritis, Guillain-Barre syndrome (acute polyneuropathy).
Vascular disorders: vasculitis, in very rare cases with transient involvement of the kidneys.
Disturbances from the skin and subcutaneous tissues: generalized reactions from the skin, including itching, hives, rashes.
If undesirable effects occur, consult a physician.
The patient should also be informed of the need to inform the physician of any unusual undesirable phenomena not described in this manual.